Supplementary Figures
The germline mutations were filtered, and nonsynonymous and synonymous mutation (N+S) differences between plasma and tissue were observed. Cutoff = 800. The different patterns between plasma and tissue, such as the high N+S mutation and somatic mutations, nonsynonymous and synonymous mutations, nonsynonymous mutations and unfavorable mutations were used as independent predictor for anlotinib responsive stratification. By integrating the merits and defects of the predictors (G+S MB, N+S MB, and UMS), TMI was generated. IDH1 mutation is an unfavorable mutation screened from nonsynonymous mutations. TMI plus IDH1 mutation status was used as predictor for anlotinib response prediction lastly. This analytical model derived from discovery cohort (n = 62 patients), and validated in an independent cohort (n = 23 patients). (B) Scoring scheme of TMI. Each patient TMI score was determined by different response analysis of G+S MB, N+S MB, and UMS, respectively. Under different predictors derive from discovery cohort, the patients grouped in anlotinib responders obtained 50 scores and those in anlotinib non-responders scored 0 as BL. For significance scoring scheme, the significant difference wilcoxon P value < 0.05 scored 1, P value < 0.01 scored 2, and P value < 0.001 scored 3, in Kaplan-Meier curve analysis for PFS and OS. The AUC > 0.7 scored 1, and the null hypothesis test P value < 0.05 scored 1, < 0.01 scored 2, and < 0.001 scored 3, in ROC curve analysis for sensitivity and specificity. Total score for each patient is calculated by above factors derived from subgroup analysis under three different regimens. TMI score is obtained by normalization calculation of the total score. BRCA2  BRCA1  ARID1A  APC  PSG5  ALK  TRIM58  ROS1  EZR  PDE1C  OR8G5  PDE4DIP  SMAD4  MET  EGFR  CBL  NTRK1  NAV3  RB1  ADAMTS12  PIK3R1  MYC  OR2T10  PIK3CA  CSMD3  SPTA1  POLR3B  ADAMTS20  RNF43  REG1B  SETD2  TRPC5  RET  ERBB3  ERBB2  CSMD1  MTOR  OR4A15  OR4C6  OR6F1  OR2T4  CDK4  POTED  SOX2  KMT2C  PRSS3  OR5L2  IKBKE  KRAS  MYH2  STK11  OR7A10  CNTNAP5 POTEI KDR CDH18 BRAF NOTCH 58 mutated genes in discovery cohort (n = 62) Mutation Frequency (%) B A Supplementary Figure 8 . IDH1 exon 4 mutation status determines anlotinib response in full TMI scored patient cohort. A total of 16 patients with full TMI score. One patient had much more mutations than the other 15 patients. Among the all patients, IDH1 mutation status in the patients with PFS > 210 days (n = 6) was significantly different from that in the patients with PFS ≤ 210 days (n = 10). These mutations are high effect nonsynonymous mutations and insertion mutations, and all exist in IDH1 exon 4 . ERBB2  BRCA1  BRCA2  ROS1  KEAP1  APC  RB1  SMAD4  PTEN  JAK1  CYP2D6  TGFBR2  RAD50  STK11  NTRK1  CDK4  SPOP  PIK3CA  RNF43  TRIM58  AKT1  IDH1  FGF4  FGFR3  TP53  CSMD3  NAV3  FGFR1  NFE2L2  JAK2  SETD2  POM121L12  SPTA1  KMT2D  LRP1B  MUTYH  PARP1  SOX2  UGT1A1  CCND1   EGFR  ALK  KRAS  BRAF  MET  HRAS  CHEK1  HGF  KIT  MSH6  MTOR  PIK3R1  PRKDC  RET  KDM5A  NRAS  MYC  FLT3  PPP2R1A  IDH2  MAP2K1  ARID1A  GATA3  DPYD  ERBB3  ESR1  CBL  CDH18  CDKN2A  ATR  BRINP3  NOTCH1  TRPC5  CHEK2  CD74  CTNNB1  EPHA5  FAT3  FGF19  GATA2 G+S MB: Germline and somatic mutation burden; N+S MB: Nonsynonymous and synonymous mutation burden; UMS: Unfavorable mutation score; TMI: Tumor mutation index; LUAD: lung adenocarcinoma; LUSC: lung squamous carcinoma.
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